NCT03374839Unknown1 期
Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients: Pilot Study Phase I/II
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 11
- 试验地点
- 1
- 主要终点
- Incidence of Treatment (adoptive T cell therapy associated to intravenous injections of Nivolumab) - Emergent Adverse Events
研究概览
简要总结
To improve the efficacy of immunotherapy for cancer, recent studies focused on specific targets to redirect the immune network toward eradicating a variety of tumors and ameliorating the self-destructive process.
A clinically relevant immune escape mechanism in melanoma is the activation of the Programmed cell Death-1 (PD-1) receptor on infiltrating T cells. By blocking PD-1 receptors with anti-PD-1 monoclonal antibodies (mAbs), T-cells are unaffected by the PD-L1 expressed on tumor cells and the patients T cells are free to respond to melanoma antigens and attack tumor cells. So the objective of this trial is to evaluate the safety and the efficacy of a combined therapy Nivolumab and adoptive T cell therapy in metastatic melanoma patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •over 18 years old with a weight ≥ 40 kg
- •Patients must have signed informed consent
- •Patients with stage IIIb, IIIc or IV metastatic melanoma (AJCC 6th edition) with at least two lesions (lymph nodes relapse, or in transit metastasis, or unresectable cutaneous metastases, or visceral metastases except bone and brain metastases) including one easily accessible and no more than 2 lines of treatment of melanoma at the metastatic stage.
- •Patients with a melanoma expressing a Braf V600 mutation can be included
- •Measurable/assessable disease in 28 days which precede the first administration of the treatment
- •A negative pregnancy test for women with childbearing potential
- •Eastern Cooperative Oncology Group (ECOG) of 0-1, Karnofsky > 80%
- •Laboratory results:
- •Haemoglobin ≥ 10 g/dl or ≥ 6,25 mmol/l; Neutrophils ≥ 1500/μl; Leukocytes ≥ 4000/μl; Lymphocytes ≥ 700/μl; Blood platelet ≥ 100.000/μl; Serum creatinine ≤ 1.5 x superior normal value or creatinine clearance (CrCl) ≥ 40 mL/min (if using the Cockcroft-Gault formula); Serum bilirubin ≤ 2.0 mg/dl or ≤ 34.2 mol/l; Total bilirubin ≤ 1.5 x superior normal value (except subjects with Gilbert Syndrome, who can have total bilirubin < 3mg/dL); Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2 x superior normal value; Lactate dehydrogenase (LDH) ≤ 1.5 x superior normal value
- •Subjects affiliated to an appropriate health insurance
- •Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception during the clinical trial. Furthermore WOCBP will be instructed to adhere to contraception for a period of 5 months after the last dose of Nivolumab.
- •Men who are sexually active with WOCBP will be instructed to adhere to contraception during the clinical trial and for a period of 7 months after the last dose of Nivolumab.
- •Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile) as well as azoospermic men do not require contraception.
- •Non inclusion Criteria:
- •Brain or bone metastases
- •Ocular melanoma
- •Chemotherapy or radiotherapy within 4 weeks before baseline (6 weeks for nitroso-ureas and mitomycin C)
- •Contraindication for the use of vasopressor agents
- •For female: the patient is pregnant or breastfeeding or not using contraception
- •For men: the patient is sexually active with WOCBP and not using contraception
- •History or current manifestations of severe progressive heart disease (congestive heart failure, coronary artery disease, uncontrolled arterial hypertension, serious rhythm disorders or ECG signs of previous myocardial infarction)
- •Patients should be excluded if they have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways except in the context of adjuvant or neoadjuvant
- •History of allergies and Adverse Drug Reaction:
- •Hypersensitivity to human albumin, TIL excipient
- •Hypersensitivity to Nivolumab or related excipients
- •History of severe hypersensitivity reaction to any monoclonal antibody
- •Hypersensitivity to aldesleukin or to one of Proleukin excipients
- •History of chronic autoimmune disease (Addison's disease, multiple sclerosis, Graves' disease, rheumatoid arthritis, systemic lupus erythematosus, etc...) except patient with active vitiligo or a history of vitiligo.
- •History of uveitis or melanoma-associated retinopathy
- •History of inflammatory bowel disease, celiac disease, or other chronic gastrointestinal conditions associated with diarrhea.
- •Presence of a second active cancer, with the exception of an in situ cervical cancer or a skin cancer different from the treated melanoma
- •Unchecked thyroid dysfunction
- •Any serious, acute or chronic illness id est active infection asking for antibiotics administration, coagulation's disorders, or any state asking for an unauthorized concomitant treatment described in this study
- •Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days before study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Subjects are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Physiologic replacement doses of systemic corticosteroids are permitted, even if > 10 mg/day prednisone equivalents. A brief course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of nonautoimmune conditions (eg, delayed-type hypersensitivity reaction caused by contact allergen) is permitted.
- •Adults under a legal protection regime (guardianship, trusteeship, "sauvegarde de justice")
排除标准
- •* Positive viral serology for HIV (human immunodeficiency virus) 1/2, p24 Ag, HTLV1, HTLV2, B and C hepatitis or syphilis
研究组 & 干预措施
TIL + IL-2 + Nivolumab
Experimental
A first cohort of 3 patients will be done to ensure that the combined treatment (TIL + IL-2 + Nivolumab) would not cause severe autoimmunity pathologies.
For this first cohort, a dose of 0.5 billion of TILs per injection will be administered. After the opinion of the Data and Safety Monitoring Committee (DSMC), the sponsor will make the decision of the second cohort of 8 patients who will receive between 1 and 20 billion of TIL.
干预措施: TIL + IL-2 + Nivolumab (Drug)
结局指标
主要结局
Incidence of Treatment (adoptive T cell therapy associated to intravenous injections of Nivolumab) - Emergent Adverse Events
时间窗: Within 12 months
Clinical and biological criteria defined by the NCI (Common Terminology Criteria for Adverse Events - version 4.0, may 2009, http://ctep.cancer.gov)
次要结局
- Efficacy of adoptive T cell therapy associated to intravenous injections of Nivolumab(At 12 months)
- Duration of the clinical response(Within 12 months of follow-up)
- Progression-free survival(From the date of the first infusion of Nivolumab until the date of the first documented progression or the date of death from any cause, whichever came first, assessed up to 12 months)
- Overall survival(From the date of the first infusion of Nivolumab until the date of death, assessed up to 12 months)
- Specific immune monitoring n°1: Evaluate the fraction of TIL specific to Melan-A and MELOE-1(Week 14 + week 18)
- Specific immune monitoring n°2: Evaluate the proportion of regulatory T cells(Day 0 (1st Nivolumab injection) + week 14 + week 18 + week 26 + week 38 + at the date of disease progression assessed up to 12 months)
- Specific immune monitoring n°3: Analyse the expression of tumor antigens(Week 10 + week 38)
- Specific immune monitoring n°4: Analyse the expression of immunosuppressive cytokines(Week 10 + week 38)
- Specific immune monitoring n°5: Analyse the expression of indoleamine 2,3-dioxygenase (IDO)(Week 10 + week 38)
- Specific immune monitoring n°6: Analyse the expression of FoxP3(Week 10 + week 38)
- Specific immune monitoring n°7: Analyse the expression of regulatory molecules(Week 10 + week 38)
- Specific immune monitoring n°8: Analyse the mutations of BRAF(Week 10 + week 38)
- Specific immune monitoring n°9: Analyse the mutations of Neuroblastoma Ras viral oncogene homolog (NRAS)(Week 10 + week 38)
- Specific immune monitoring n°10: Analyse the mutations of proto-oncogene ckit (cKit)(Week 10 + week 38)
- Specific immune monitoring n°11: Determine the percentage of reactive T cells in the expanded cells(Week 10)
- Specific immune monitoring n°12: Determine the phenotype of the expanded T cells(Week 10)
- Specific immune monitoring n°13: Test TIL reactivity(Week 10)
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian CancerMetastatic Ovarian CancerMetastatic Fallopian Tube CancerPeritoneal CancerNCT04611126Inge Marie Svane6
进行中（未招募）
1 期
Cell based treatment in combination with three checkpoint inhibitors for ovarian-, fallopian tube and primary peritoneal cancer.Advanced Ovarian-, Fallopian Tube- and Primary Peritoneal Cancer.MedDRA version: 20.0Level: LLTClassification code 10033130Term: Ovarian cancer NOSSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10016183Term: Fallopian tube cancer NOSSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10052171Term: Peritoneal carcinomaSystem Organ Class: 100000004864EUCTR2020-002738-34-DKational Center for Cancer Immune Therapy18
进行中（未招募）
2 期
Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHNSquamous Cell Carcinoma of the Head and NeckNCT03341936Dana-Farber Cancer Institute29
已完成
2 期
Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell CarcinomaRenal Cell CarcinomaNCT03297593Swiss Group for Clinical Cancer Research74
进行中（未招募）
2 期
Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung CancerLung CancerNCT06055465Chinese University of Hong Kong37